LA 40221
Latest Information Update: 28 Sep 1995
At a glance
- Originator Sanofi-Synthelabo
- Class Antimalarials
- Mechanism of Action Calmodulin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 28 Sep 1995 No-Development-Reported for Malaria in France (Unknown route)
- 07 Nov 1994 No-Development-Reported for Malaria in Africa (Unknown route)
- 07 Nov 1994 No-Development-Reported for Malaria in Philippines (Unknown route)